Although this is the first study evaluating miR155 combined with IL6/BAFF-R expression in salivary glands as B-cell activation biomarkers related to lymphomagenesis in pSS, its retrospective design and the limited sample size of patients experiencing NHL evolution are limitations that should be considered. This evidence concerns the gene IL6 and non-Hodgkin lymphoma.